LofyGang resurfaces with LofyStealer disguised as Minecraft hack, exfiltrating IBANs and passwords to 24.152.36[.]241, ...
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
Hosted on MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
The Cabinet Office’s decision to end Capita’s contract to administer the Royal Mail pension follows heavy criticism of the supplier’s work on the civil service pension contract Continue Reading ...
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. David Kindness is a Certified Public ...
Mitchell Grant is a self-taught investor with over 5 years of experience as a financial trader. He is a financial content strategist and creative content editor. Khadija Khartit is a strategy, ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results